ラニナミビル
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2016/09/28 02:14:21」(JST)
[Wiki en表示]
Laninamivir
|
Systematic (IUPAC) name |
(4S,5R,6R)-5-acetamido-4-carbamimidamido-6-[(1R,2R)-3-hydroxy-2-methoxypropyl]-5,6-dihydro-4H-pyran-2-carboxylic acid
|
Clinical data |
Routes of
administration |
Inhalation |
Identifiers |
CAS Number |
203120-17-6 N |
ATC code |
none |
PubChem |
CID 502272 |
ChemSpider |
439182 Y |
UNII |
B408IW3GL5 Y |
ChEMBL |
CHEMBL466246 Y |
Chemical data |
Formula |
C13H22N4O7 |
Molar mass |
346.33638 g/mol |
SMILES
-
O=C(O)C=1O[C@@H]([C@H](OC)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](/N=C(\N)N)C=1
|
InChI
-
InChI=1S/C13H22N4O7/c1-5(19)16-9-6(17-13(14)15)3-8(12(21)22)24-11(9)10(23-2)7(20)4-18/h3,6-7,9-11,18,20H,4H2,1-2H3,(H,16,19)(H,21,22)(H4,14,15,17)/t6-,7+,9+,10+,11+/m0/s1 Y
-
Key:QNRRHYPPQFELSF-CNYIRLTGSA-N Y
|
NY (what is this?) (verify) |
Laninamivir (CS-8958) is a neuraminidase inhibitor which is being researched for the treatment and prophylaxis of Influenzavirus A and Influenzavirus B.[1] It is currently in Phase III clinical trials.[2] It is a long-acting neuraminidase inhibitor administered by nasal inhalation.[3]
Laninamivir was approved for influenza treatment in Japan in 2010 and for prophylaxis in 2013. It is currently marketed under the name Inavir by Daiichi Sankyo. Biota Pharmaceuticals [4] and Daiichi Sankyo co-own Laninamivir. On 1 April 2011, BARDA awarded up to an estimated U$231m to Biota Pharmaceuticals (Formerly Biota Holdings Ltd) wholly owned subsidiary, Biota Scientific Management Pty Ltd, for the advanced development of Laninamivir in the US.[5] It is under clinical evaluations in other countries.[3]
References
- ^ Yamashita M, Tomozawa T, Kakuta M, Tokumitsu A, Nasu H, Kubo S (January 2009). "CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity". Antimicrobial Agents and Chemotherapy. 53 (1): 186–92. doi:10.1128/AAC.00333-08. PMC 2612152. PMID 18955520.
- ^ Hayden F (January 2009). "Developing new antiviral agents for influenza treatment: what does the future hold?". Clinical Infectious Diseases. 48. Suppl 1 (S1): S3–13. doi:10.1086/591851. PMID 19067613.
- ^ a b Samson, M; Pizzorno, A; Abed, Y; Boivin, G (May 2013). "Influenza virus resistance to neuraminidase inhibitors.". Antiviral Research. 98 (2): 174–85. doi:10.1016/j.antiviral.2013.03.014. PMID 23523943.
- ^ http://www.biotapharma.com
- ^ http://www.biotapharma.com/?page=1021001&subpage=1021019
RNA virus antivirals (primarily J05, also S01AD and D06BB)
|
|
Hepatitis C |
NS3/4A protease inhibitors (–previr) |
- Asunaprevir
- Boceprevir
- Faldaprevir‡
- Grazoprevir
- Paritaprevir
- Simeprevir
- Telaprevir
|
|
NS5A inhibitors (–asvir) |
- Daclatasvir
- Elbasvir
- Ledipasvir
- MK-3682
- MK-8408
- Odalasvir†
- Ombitasvir
- Ravidasvir†
- Samatasvir†
- Velpatasvir
|
|
NS5B RNA polymerase inhibitors (–buvir) |
- Beclabuvir†
- Dasabuvir
- Deleobuvir§
- Filibuvir§
- Setrobuvir§
- Sofosbuvir
- Radalbuvir†
|
|
Combination drugs |
- Elbasvir/grazoprevir
- Ledipasvir/sofosbuvir
- Ombitasvir/paritaprevir/ritonavir
- Sofosbuvir/daclatasvir
- Velpatasvir/sofosbuvir
|
|
|
Picornavirus |
|
|
Anti-influenza agents |
- adamantane derivatives/M2 inhibitors (Adapromine
- Amantadine
- Rimantadine)
- neuraminidase inhibitors/release phase (Oseltamivir
- Zanamivir
- Peramivir, Laninamivir†)
|
|
Multiple/general |
Interferon |
- Interferon alfa 2b
- Peginterferon alfa-2a#
|
|
Multiple/unknown |
- BCX4430
- Favipiravir
- MK-608§
- Moroxydine
- Ribavirin#/Taribavirin†
- Triazavirin
|
|
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
|
Influenza
|
|
General topics |
- Research
- Vaccine
- Treatment
- Genome sequencing
- Reassortment
- Superinfection
- Flu season
|
|
Viruses |
- Orthomyxoviridae
- Influenza A
- Influenza B
- Influenza C
|
|
Influenza A virus
subtypes
|
- H1N1
- H1N2
- H2N2
- H2N3
- H3N1
- H3N2
- H3N8
- H5N1
- H5N2
- H5N3
- H5N6
- H5N8
- H5N9
- H6N1
- H7N1
- H7N2
- H7N3
- H7N4
- H7N7
- H7N9
- H9N2
- H10N7
|
|
H1N1 |
Pandemics |
- 1918 ("Spanish flu")
- 2009 ("swine flu")
|
|
Science |
|
|
|
H5N1 |
Outbreaks |
- Croatia (2005)
- India (2006)
- UK (2007)
- West Bengal (2008)
|
|
Science |
- Genetic structure
- Transmission and infection
- Global spread
- Vaccine
- Human mortality
- Social impact
- Pandemic preparation
|
|
|
Treatments |
Antiviral drugs |
- Adamantane derivatives
- Neuraminidase inhibitor
- Oseltamivir
- Laninamivir
- Peramivir
- Zanamivir
- Peramivir (experimental)
- Umifenovir
|
|
Vaccines |
- Live attenuated influenza vaccine
- Fluzone
- Pandemrix
|
|
|
Pandemics and
epidemics
|
Pandemics |
- "Russian flu" (1889–1890)
- "Spanish flu" (1918)
- "Asian flu"
- "Hong Kong flu" (1968)
- 2009
|
|
Epidemics |
- "Russian flu" (1977–1978)
- "Fujian flu" (H3N2)
|
|
|
Non-human |
Mammals |
- Canine
- Feline
- Equine
- Swine
|
|
Non-mammals |
|
|
|
Complications |
- Acute bronchitis
- Bronchiolitis
- Croup
- Otitis media
- Pharyngitis
- Pneumonia
- Sinusitis
- Strep throat
|
|
Related topics |
|
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
English Journal
- Evaluation of a dry powder delivery system for laninamivir in a ferret model of influenza infection.
- Panozzo J1, Oh DY2, Margo K3, Morton DA4, Piedrafita D5, Mosse J6, Hurt AC7.
- Antiviral research.Antiviral Res.2015 Aug;120:66-71. doi: 10.1016/j.antiviral.2015.05.007. Epub 2015 May 26.
- Laninamivir is a long-acting antiviral requiring only a single dose for the treatment of influenza infection, making it an attractive alternative to existing neuraminidase inhibitors that require multiple doses over many days. Like zanamivir, laninamivir is administered to patients by inhalation of
- PMID 26022199
- Influenza viruses with B/Yamagata- and B/Victoria-like neuraminidases are differentially affected by mutations that alter antiviral susceptibility.
- Farrukee R1, Leang SK2, Butler J2, Lee RT3, Maurer-Stroh S4, Tilmanis D2, Sullivan S2, Mosse J5, Barr IG2, Hurt AC6.
- The Journal of antimicrobial chemotherapy.J Antimicrob Chemother.2015 Jul;70(7):2004-12. doi: 10.1093/jac/dkv065. Epub 2015 Mar 18.
- OBJECTIVES: The burden of disease due to influenza B is often underestimated. Clinical studies have shown that oseltamivir, a widely used neuraminidase inhibitor (NAI) antiviral drug, may have reduced effectiveness against influenza B viruses. Therefore, it is important to study the effect of neuram
- PMID 25786478
- In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against clinical isolates of the influenza virus circulating in the Japanese 2013-2014 season.
- Ikematsu H1, Kawai N2, Iwaki N2, Kashiwagi S2.
- Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.J Infect Chemother.2015 May 30. pii: S1341-321X(15)00124-5. doi: 10.1016/j.jiac.2015.05.004. [Epub ahead of print]
- To assess the extent of viral resistance, we measured the 50% inhibitory concentration (IC50) of neuraminidase inhibitors (NAIs) for the influenza virus isolates in the 2013-2014 influenza season and compared the results to those of the 2010-2011 to 2012-2013 influenza seasons. Viral isolation was d
- PMID 26096495
Japanese Journal
- 医薬品副作用データベース(JADER)を用いたノイラミニダーゼ 阻害剤と精神神経症状の関連性の検討
- イナビル®添加乳糖中のβ-ラクトグロブリンおよびその糖鎖付加体が原因と推察されたアナフィラキシーの1例
- Influenza Virus Shedding in Laninamivir-Treated Children upon Returning to School
Related Links
- Title: Laninamivir Vocal: めらみぽっぷ (Meramipop) Arrangement: NSY Circle: monochrome-coat Album: Object Release Date: May 26, 2013 (Reitaisai 10) htt...
- 1. Expert Rev Anti Infect Ther. 2011 Oct;9(10):851-7. doi: 10.1586/eri.11.112. Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza. Ikematsu H(1), Kawai N. Author ...
Related Pictures
★リンクテーブル★
[★]
- 英
- laninamivir
- 化
- ラニナミビルオクタン酸エステル
- 商
- イナビル Inavir
- 関
- 長時間作用型ノイラミニダーゼ阻害剤、インフルエンザウイルス
- 抗ウイルス剤
作用機序
- ラニナミビルオクタン酸エステル水和物の活性代謝物ラニナミビルは、A型及びB型インフルエンザウイルスのノイラミニダーゼを選択的に阻害し(IC50:1.29~38.8nM)、新しく形成されたウイルスの感染細胞からの遊離を阻害することにより、ウイルスの増殖を抑制する。